BPI-17509

BPI-17509 is an orally bioavailable, small-molecule pan-FGFR inhibitor developed by Betta Pharmaceuticals. It is designed to selectively target and inhibit fibroblast growth factor receptors, specifically FGFR1, FGFR2, and FGFR3. These receptors are frequently dysregulated in various malignancies through mechanisms such as gene fusions, mutations, or amplifications, leading to constitutive signaling that promotes cell proliferation, survival, and angiogenesis. BPI-17509 is currently being evaluated in Phase I clinical trials for the treatment of advanced solid tumors, with a particular focus on patients harboring FGFR aberrations, including FGFR2 fusion-positive cholangiocarcinoma and FGFR3-altered bladder cancer.